trending Market Intelligence /marketintelligence/en/news-insights/trending/lzG9eCEt04zLgRdpRVrePA2 content esgSubNav
In This List

FSD Pharma receives approval to list on Nasdaq

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


FSD Pharma receives approval to list on Nasdaq

FSD Pharma Inc. received approval to list its shares on the Nasdaq Capital Market.

The Cobourg, Ontario-based company will have its class B subordinate voting shares, a type of common stock, listed on Nasdaq. Trading of the stocks will start in the near future, the company said, without giving a date.

FSD Pharma is already listed on the Canadian Securities Exchange. The company in October said it is consolidating its class A multiple voting shares and its class B subordinate voting shares, each on a 1-to-201 basis. Following consolidation, FSD Pharma will have 72 issued and outstanding class A shares, representing 276,660 votes or about 72% of the company's voting rights.

FSD Pharma is a medical cannabis company focused on developing indoor-grown pharmaceutical-grade cannabis.